Cytosorbents (NASDAQ:CTSO) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Cytosorbents (NASDAQ:CTSOFree Report) in a report released on Saturday morning. The firm issued a hold rating on the medical research company’s stock.

A number of other research analysts have also recently commented on the company. HC Wainwright restated a neutral rating and issued a $1.00 price target on shares of Cytosorbents in a research report on Tuesday, May 7th. B. Riley reaffirmed a buy rating and issued a $3.00 price target on shares of Cytosorbents in a research note on Wednesday.

Get Our Latest Research Report on Cytosorbents

Cytosorbents Stock Performance

CTSO stock opened at $0.97 on Friday. The company has a current ratio of 1.49, a quick ratio of 1.21 and a debt-to-equity ratio of 0.10. The business’s fifty day moving average price is $0.89 and its two-hundred day moving average price is $1.08. Cytosorbents has a fifty-two week low of $0.78 and a fifty-two week high of $4.29.

Cytosorbents (NASDAQ:CTSOGet Free Report) last posted its quarterly earnings data on Thursday, May 9th. The medical research company reported ($0.12) earnings per share for the quarter, hitting the consensus estimate of ($0.12). The firm had revenue of $9.79 million for the quarter, compared to analysts’ expectations of $9.78 million. Cytosorbents had a negative return on equity of 129.89% and a negative net margin of 75.07%. During the same quarter last year, the business earned ($0.17) EPS. As a group, analysts anticipate that Cytosorbents will post -0.35 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Key Client Fiduciary Advisors LLC raised its stake in Cytosorbents by 188.0% in the first quarter. Key Client Fiduciary Advisors LLC now owns 34,557 shares of the medical research company’s stock valued at $33,000 after purchasing an additional 22,557 shares in the last quarter. Raymond James & Associates acquired a new position in Cytosorbents during the fourth quarter worth about $56,000. CM Management LLC raised its stake in Cytosorbents by 98.8% during the first quarter. CM Management LLC now owns 825,000 shares of the medical research company’s stock worth $784,000 after acquiring an additional 410,000 shares in the last quarter. Sargent Investment Group LLC raised its stake in Cytosorbents by 4.1% during the fourth quarter. Sargent Investment Group LLC now owns 1,308,747 shares of the medical research company’s stock worth $1,453,000 after acquiring an additional 51,699 shares in the last quarter. Finally, Neuberger Berman Group LLC raised its stake in Cytosorbents by 19.9% during the fourth quarter. Neuberger Berman Group LLC now owns 1,801,799 shares of the medical research company’s stock worth $1,997,000 after acquiring an additional 299,103 shares in the last quarter. Institutional investors and hedge funds own 32.87% of the company’s stock.

Cytosorbents Company Profile

(Get Free Report)

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.

Featured Articles

Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.